Alecensa reduced risk of disease progression or death in Alk-positive metastatic NSCLC

In follow-up data from the phase III ALEX study, an initial treatment Alecensa (alectinib) significantly reduced the risk of disease progression or death by 57 percent (hazard ratio= 0.43, 95 percent CI: 0.32-0.58) compared to crizotinib after two years of follow-up in people with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, as assessed by the investigator.